Grit Biotechnology secures funds for development of pipeline programmes
11 Sep 2023
Phase 1Gene TherapyCell TherapyPhase 2IND
Preview
Source: Pharmaceutical Technology
A tumour-infiltrating lymphocyte therapy of Grit Biotechnology, GT101 is set to enter the Phase II trial by year-end. Credit: CI Photos/Shutterstock.com.
Preview
Source: Pharmaceutical Technology
Cell therapy company Grit Biotechnology has secured more than $60m (436.72m yuan) in a Series B funding round to support the development of its pipeline programmes.
China International Capital Corporation led the financing round, which saw investments from Liando Group, Qianhai Ark, Yuanhe Capital and HeFangTian Venture Partnership.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - ustekinumab biosimilar GlobalData
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - tenecteplase biosimilar GlobalData
View allCompanies IntelligenceChina International Capital Corp LtdMatrix Partners ChinaDecheng Capital LLCYuanhe CapitalGritView all
Grit’s existing investors, namely Sherpa Healthcare Partners, Matrix Partners China and Decheng Capital, also took part in the financing round.
Grit plans to utilise the investment proceeds to support the development of its tumour-infiltrating lymphocyte (TIL) pipeline.
These funds will also be used for the Phase II clinical trial of TIL therapy, GT101, and progress next-gen gene-edited TIL products.
GT101 is set to enter the Phase II trial by year-end.
Grit Biotechnology was established in 2019 and is focused on offering transformative therapies for cancer.
The company uses four technology platforms for developing gene-edited TIL products: StemTexp, StaViral, KOReTIL and genome-wide CRISPR/Cas9 screening platform ImmuT Finder.
GT201 has received new drug application clearance from the China Food and Drug Administration and is currently being evaluated in Phase I trials while GT316 is in investigator-initiated trials in the region.
Grit has a 10,000m² GMP-level cell therapy production facility in Suzhou with a workforce of more than 100 specialists.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.By Cytiva Thematic
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.